Literature DB >> 22576024

New invasive patterns as a prognostic factor for superficial esophageal cancer.

Eisuke Ito1, Soji Ozawa, Hiroshi Kijima, Akihito Kazuno, Takayuki Nishi, Osamu Chino, Hideo Shimada, Makiko Tanaka, Shigeaki Inoue, Sadaki Inokuchi, Hiroyasu Makuuchi.   

Abstract

BACKGROUND: Prognostic factors for superficial esophageal cancer cannot be limited to such factors as lymph node metastasis (N factor), depth of tumor invasion (T factor), and genetic alterations. The purpose of this study was to examine whether invasive growth patterns of tumors, such as infiltrative growth pattern c (INFc) and budding, represent new useful prognostic factors for superficial esophageal cancer.
METHODS: We investigated 87 cases of superficial esophageal cancer in patients treated with radical surgery. First, the invasive growth pattern of the tumor was pathologically evaluated based on the traditional infiltrative growth pattern (INF) classification. Next, new INF criteria were proposed, and the invasive pattern was re-evaluated. We also investigated budding (Bud) in the stroma of the invasive frontal lesion.
RESULTS: When the patients were divided into two groups, with and without an INFc component, the group with an INFc component had a poorer outcome than the group without an INFc component. When the group with an INFc component was defined as "new INFc", new INFc was correlated with the T factor (p = 0.006) and the ly factor (lymphatic invasion) (p = 0.041). Bud was correlated with the T factor (p = 0.001), the N factor (p = 0.030), and new INFc (p < 0.001). An analysis of survival revealed new INFc (p = 0.002) and Bud (p = 0.006) to be prognostic factors. The survival of the group with new INFc(+)/Bud(+) was poorer than that with new INFc(-)/Bud(-) (p = 0.007).
CONCLUSIONS: New INFc and Bud, which represent new invasive patterns, were prognostic factors for superficial esophageal cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22576024     DOI: 10.1007/s00535-012-0587-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  23 in total

1.  How can we diagnose the early stage of esophageal cancer? Endoscopic diagnosis.

Authors:  M Endo; K Takeshita; M Yoshida
Journal:  Endoscopy       Date:  1986-09       Impact factor: 10.093

2.  Endoscopic screening for esophageal cancer in 788 patients with head and neck cancers.

Authors:  H Makuuchi; T Machimura; H Shimada; K Mizutani; O Chino; Y Kise; T Nishi; H Tanaka; T Mitomi; M Horiuchi; M Sakai; J Gotoh; J Sasaki; Y Osamura
Journal:  Tokai J Exp Clin Med       Date:  1996-10

3.  Immunohistochemical MUC1 (DF3 antigen) expression of human esophageal squamous cell carcinoma.

Authors:  H Kijima; O Chino; G Oshiba; H Tanaka; T Kenmochi; Y Kise; H Shimada; Y Abe; T Tokunaga; H Yamazaki; M Nakamura; M Tanaka; H Makuuchi; Y Ueyama
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

4.  Clinicopathological significance of tumor nest configuration in patients with esophageal squamous cell carcinoma.

Authors:  Y Nakanishi; A Ochiai; H Kato; Y Tachimori; H Igaki; S Hirohashi
Journal:  Cancer       Date:  2001-03-15       Impact factor: 6.860

5.  Accumulation of p53 in esophageal squamous cell carcinoma.

Authors:  O Chino; H Kijima; H Shimada; T Nishi; H Tanaka; Y Kise; T Kenmochi; S Himeno; T Machimura; M Tanaka; S Inokuchi; T Tajima; R Y Osamura; H Makuuchi
Journal:  Int J Mol Med       Date:  2001-10       Impact factor: 4.101

6.  Outcomes of endoscopic submucosal dissection versus endoscopic mucosal resection in management of superficial squamous esophageal neoplasms outside Japan.

Authors:  Anthony Yuen Bun Teoh; Philip Wai Yan Chiu; Dennis Kwok Yu Ngo; Simon Kin Hung Wong; James Yun Wong Lau; Enders Kwok Wai Ng
Journal:  J Clin Gastroenterol       Date:  2010-10       Impact factor: 3.062

7.  Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

Authors:  H Ueno; J Murphy; J R Jass; H Mochizuki; I C Talbot
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

8.  Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor.

Authors:  Masahiko Koike; Yasuhiro Kodera; Yuichi Itoh; Goro Nakayama; Michitaka Fujiwara; Nobuyuki Hamajima; Akimasa Nakao
Journal:  Ann Surg Oncol       Date:  2008-04-12       Impact factor: 5.344

9.  Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma.

Authors:  Takashi Okuyama; Tetsuro Nakamura; Masahiko Yamaguchi
Journal:  Dis Colon Rectum       Date:  2003-10       Impact factor: 4.585

10.  Histological grading in gastric cancer by Ming classification: correlation with histopathological subtypes, metastasis, and prognosis.

Authors:  Thomas Luebke; Stephan E Baldus; Guido Grass; Elfriede Bollschweiler; Jürgen Thiele; Hans-Peter Dienes; Arnulf H Hoelscher; Stefan P Moenig
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.282

View more
  13 in total

1.  Tumor budding is an adverse prognostic marker in intestinal-type sinonasal adenocarcinoma and seems to be unrelated to epithelial-mesenchymal transition.

Authors:  Valeria Maffeis; Rocco Cappellesso; Francesca Galuppini; Vincenza Guzzardo; Alessia Zanon; Diego Cazzador; Enzo Emanuelli; Laura Ventura; Alessandro Martini; Ambrogio Fassina
Journal:  Virchows Arch       Date:  2020-01-24       Impact factor: 4.064

2.  Characteristics of Postoperative Recurrence in Lymph Node-Negative Superficial Esophageal Carcinoma.

Authors:  Yohei Ozawa; Takashi Kamei; Toru Nakano; Yusuke Taniyama; Shigehito Miyagi; Noriaki Ohuchi
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

3.  Prognostic Significance of CD44 and Orthopedia Homeobox Protein (OTP) Expression in Pulmonary Carcinoid Tumours.

Authors:  George Papaxoinis; Daisuke Nonaka; Ciara O'Brien; Benjamin Sanderson; Piotr Krysiak; Wasat Mansoor
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 4.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

Review 5.  Comparison of two major staging systems of esophageal cancer-toward more practical common scale for tumor staging.

Authors:  Harushi Udagawa; Masaki Ueno
Journal:  Ann Transl Med       Date:  2018-02

6.  Curative Criteria After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinomas.

Authors:  T Mizumoto; T Hiyama; S Oka; N Yorita; K Kuroki; M Kurihara; Y Yoshifuku; Y Sanomura; Y Urabe; Y Murakami; K Arihiro; S Tanaka; K Chayama
Journal:  Dig Dis Sci       Date:  2018-03-21       Impact factor: 3.199

7.  EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas.

Authors:  Devraj Basu; Arnaud F Bewley; Steven M Sperry; Kathleen T Montone; Phyllis A Gimotty; Kati Rasanen; Nicole D Facompre; Gregory S Weinstein; Hiroshi Nakagawa; J Alan Diehl; Anil K Rustgi; Meenhard Herlyn
Journal:  Mol Cancer Ther       Date:  2013-08-12       Impact factor: 6.261

8.  Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma.

Authors:  Makiko Tanaka; Hiroshi Kijima; Hideo Shimada; Hiroyasu Makuuchi; Soji Ozawa; Sadaki Inokuchi
Journal:  Mol Med Rep       Date:  2015-06-19       Impact factor: 2.952

9.  High-Grade Tumor Budding Stratifies Early-Stage Cervical Cancer with Recurrence Risk.

Authors:  Bangxing Huang; Jing Cai; Xia Xu; Shuang Guo; Zehua Wang
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

10.  Lymphatic invasion is a significant indicator of poor patient prognosis in lung squamous cell carcinoma.

Authors:  Ryota Masuda; Hiroshi Kijima; Madoka Nito; Atsushi Wada; Tomohiko Matsuzaki; Yoichiro Ikoma; Kenei Nakazato; Daisuke Masuda; Makiko Tanaka; Hiroyuki Kobayashi; Sadaki Inokuchi; Masayuki Iwazaki
Journal:  Mol Med Rep       Date:  2017-02-28       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.